Skip to main content
Premium Trial:

Request an Annual Quote

Roche Ponies Up $70 Million for Affy Access

NEW YORK, Jan. 30-Roche will pay Affymetrix $70 million to use its GeneChip technology to develop new diagnostics, Affymetrix said today.


Roche will have nonexclusive rights to Affy's microarrays and systems for up to 18 years. The pharmaceutical company will use the platform in genotyping, gene expression, and resequencing studies to create new tests for disease.


Working together, the two companies will develop and validate tests and conduct clinical trials. The partners will also jointly create instrument systems that can be used by diagnostic laboratories to scan microarrays.


Under the terms of the deal, Affymetrix may also receive royalties on diagnostic kit sales and milestone payments for scientific and commercial successes.


For further information, see the company statement.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.